Perpetual Ltd’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$613K Sell
809
-1,598
-66% -$1.21M 0.01% 283
2026
Q2
$1.5M Buy
2,407
+262
+12% +$178K 0.02% 193
2026
Q1
$1.66M Hold
2,145
– – 0.03% 175
2025
Q4
$1.66M Buy
+2,145
New +$1.46M 0.02% 190
2024
Q4
– Sell
-69,706
Closed -$73.3M – 449
2024
Q3
$73.3M Sell
69,706
-3,819
-5% -$4.25M 0.79% 46
2024
Q2
$77.3M Sell
73,525
-11,254
-13% -$10.9M 0.84% 38
2024
Q1
$81.6M Sell
84,779
-15,440
-15% -$14.7M 0.8% 47
2023
Q4
$88M Sell
100,219
-6,335
-6% -$5.22M 0.91% 34
2023
Q3
$87.7M Sell
106,554
-7,883
-7% -$6.2M 0.91% 37
2023
Q2
$82.2M Sell
114,437
-7,226
-6% -$5.57M 0.71% 48
2023
Q1
$100M Buy
+121,663
New +$91.8M 0.86% 35
2020
Q3
$3.33M Sell
5,953
-906
-13% -$549K 0.24% 133
2020
Q2
$4.28M Buy
6,859
+313
+5% +$178K 0.4% 73
2020
Q1
$3.2M Buy
+6,546
New +$2.7M 0.45% 92
2017
Q3
– Sell
-13,971
Closed -$6.86M – 227
2017
Q2
$6.86M Hold
13,971
– – 0.54% 59
2017
Q1
$5.27M Hold
13,971
– – 0.52% 58
2016
Q4
$5.13M Buy
13,971
+2,514
+22% +$956K 0.78% 36
2016
Q3
$4.61M Buy
+11,457
New +$4.6M 0.38% 69

Other funds holding REGN

Perpetual Ltd's REGN Position: Q3 2026 in Review

Perpetual Ltd reduced its Regeneron Pharmaceuticals (REGN) stake by 66% in Q3 2026, selling an estimated $1.21M and leaving 809 shares worth $613K. The position accounts for 0.01% of the portfolio, ranked #283.

Perpetual Ltd first reported a position in REGN in Q3 2016 and has held it in 18 quarters since. The position peaked at $100M in Q1 2023. 656 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Perpetual Ltd held 809 shares of Regeneron Pharmaceuticals worth $613K as of Q3 2026.
  • Perpetual Ltd sold 1,598 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $1.21M.
  • Regeneron Pharmaceuticals made up 0.01% of Perpetual Ltd's portfolio in Q3 2026, its #283 holding.
  • Perpetual Ltd first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 18 quarters since.
  • Perpetual Ltd's Regeneron Pharmaceuticals position peaked at $100M in Q1 2023.
  • 656 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Perpetual Ltd's 13F filing for Q3 2026, filed 13 Oct 2026.